| Ticker Symbol: | BVF |
|---|---|
| Exchange: | NYSE |
| Contact Info: | |
| CEO/President: | |
| Industry: | Medical - Drugs / Standard Industry Code: 2834 |
| Description: | Biovail Corporation is a specialty pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products utilizing advanced drug-delivery technologies. Biovail\'s position of leadership as an innovative developer of medicines is based on its use of advanced drug- delivery technologies that provide significant therapeutic advantages over existing formulations. The Company has a number of proprietary drug-delivery platforms that can be applied to existing in-market drugs to develop enhanced formulations that offer more consistent drug release, greater patient compliance and, potentially, superior efficacy and lower incidence of side effects. |
| Shares Outstanding: | 158,710 (000) | Market Value: | 1,387,170 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 59.02% | Number of Inst.Shareholders: | 17.00% |
| Last Quarter Sales: | 181.09 ($Mil.) | Last Quarter Net Income: | 48.44 ($Mil.) |
| Last Quarter EPS: | 0.35 | P/E Ratio: | 5 |
| Most Recent Earnings: | 0.32 on 11/06/08 | Earnings Per Share: | 0.30 |
| Most Recent Split: | Annual Dividend Rate: | 1.5 | |
| Most Recent Dividend: | 0.375 on 08/21/08 | Annual Dividend Yield: | 17.16% |


| PFIZER INC | -28.40 | 15.92 | |
| JOHNSON AND JOH | -13.30 | 59.27 | |
| BRISTOL MYERS S | -24.10 | 19.70 | |
| SCHERING PLOUGH | -43.90 | 15.18 | |
| MERCK CO INC | -55.10 | 25.99 |
